Clinical Trials

The first interventional study to show that ctDNA can guide adjuvant therapy decisions.

Results validated after 5 years of follow-up were generated using an earlier version of our technology.

In a landmark study, patients with mismatch repair–deficient (dMMR) cancers underwent immunotherapy alone (without surgery), chemotherapy, or radiation.

Our technology served as a real-time method to track patient's response to treatment.

It identified response to therapy earlier than traditional imaging methods.